MaxCyte’s new clinical and commercial licence agreement with Caribou Biosciences, which allows the use of its proprietary Flow Electroporation technology for Caribou’s CRISPR gene-edited allogeneic T-cell therapy programmes is the latest in a series of late-stage clinical and commercial collaborati
07 May 2020
MaxCyte: Gold standard technology draws CRISPR pioneer Caribou
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
MaxCyte: Gold standard technology draws CRISPR pioneer Caribou
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
07 May 2020 -
Author:
Emma Ulker -
Pages:
3
MaxCyte’s new clinical and commercial licence agreement with Caribou Biosciences, which allows the use of its proprietary Flow Electroporation technology for Caribou’s CRISPR gene-edited allogeneic T-cell therapy programmes is the latest in a series of late-stage clinical and commercial collaborati